Wednesday, November 07, 2018 The PR.15 trial, a Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer has been permanently closed and no further ethics approvals or folow up data are required. The notification of permanent trial closure is posted on the CCTG website under the "Toolbox" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure/ as well as on the PR.15 trial page. The primary publication was distributed to sites in September, 2018 Eligibility: . Histologically confirmed CaP . PSA < 20 ng /ml . TNM classification . T2b to T2c, GS < 8/10 or . T1c-T2a GS 7/10 or . T1c-T2a, GS less than or equal to 6/10, 10 less than or equal to PSA < 20 . Prostate volume less than or equal to 75 cc Objectives: Primary: The primary objective of this feasibility study is to assess the ability of Canadian investigators from multiple institutions to randomize patients to curative intent IGRT or IGRT with HDR brachytherapy boost. Secondary: Acute GU and GI adverse events; Quality assurance; Treatment compliance If you have questions please contact the study coordinator Magda Monreal
